Geode Capital Management
NGM

Geode Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Geode Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-983,836
Closed -$1.56M – 4702
2024
Q1 		$1.56M Buy
983,836
+62,226
+7% +$92.3K ﹤0.01% 3207
2023
Q4 		$792K Buy
921,610
+34,709
+4% +$30.5K ﹤0.01% 3438
2023
Q3 		$949K Buy
886,901
+35,945
+4% +$74.4K ﹤0.01% 3348
2023
Q2 		$2.2M Buy
850,956
+60,119
+8% +$214K ﹤0.01% 3080
2023
Q1 		$3.23M Buy
790,837
+42,113
+6% +$195K ﹤0.01% 2824
2022
Q4 		$3.76M Buy
748,724
+11,408
+2% +$71.5K ﹤0.01% 2804
2022
Q3 		$9.64M Buy
737,316
+8,702
+1% +$132K ﹤0.01% 2289
2022
Q2 		$9.34M Buy
728,614
+26,300
+4% +$364K ﹤0.01% 2299
2022
Q1 		$10.7M Buy
702,314
+4,340
+0.6% +$67.7K ﹤0.01% 2304
2021
Q4 		$12.4M Buy
697,974
+54,101
+8% +$1.04M ﹤0.01% 2306
2021
Q3 		$13.5M Buy
643,873
+68,077
+12% +$1.5M ﹤0.01% 2243
2021
Q2 		$11.4M Buy
575,796
+117,483
+26% +$2.75M ﹤0.01% 2372
2021
Q1 		$13.3M Buy
458,313
+112,796
+33% +$3.16M ﹤0.01% 2151
2020
Q4 		$10.5M Buy
345,517
+44,258
+15% +$968K ﹤0.01% 2148
2020
Q3 		$4.79M Buy
301,259
+56,879
+23% +$1.04M ﹤0.01% 2423
2020
Q2 		$4.82M Buy
244,380
+9,592
+4% +$183K ﹤0.01% 2356
2020
Q1 		$2.89M Buy
234,788
+47,697
+25% +$779K ﹤0.01% 2463
2019
Q4 		$3.46M Buy
187,091
+92,660
+98% +$1.35M ﹤0.01% 2672
2019
Q3 		$1.31M Sell
94,431
-4,750
-5% -$71.3K ﹤0.01% 3137
2019
Q2 		$1.45M Buy
+99,181
New +$1.45M ﹤0.01% 3103

Geode Capital Management's NGM Position: Q2 2024 in Review

Geode Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 983,836 shares — an estimated $1.56M sold.

Geode Capital Management first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $13.5M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Geode Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Geode Capital Management sold 983,836 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $1.56M.
  • Geode Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
  • Geode Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $13.5M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.